TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8163717

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 14 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 6 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 13 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 7 days (discontinued)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours)
Number of subjects: 12
Study: 2465517

Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 370
Study: 29724590

Group type: EXPERIMENTAL
Intervention: PFNA Augmentation group
Number of subjects: 223

Group type: COMPARATOR
Intervention: PFNA group
Number of subjects: 223
Study: 28488687

Group type: EXPERIMENTAL
Intervention: Diet intervention based on Nordic Nutrition Recommendations (NNR) 2004
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (ND-group)
Number of subjects: 61
Study: 26271050

Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Multiple-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Multiple-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Number of subjects: 161
Study: 23975475

Group type: EXPERIMENTAL
Intervention: Affect management (AM) intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard skills-based HIV prevention intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: General health promotion (HP) intervention
Number of subjects: 377
Study: 21414384

Group type: EXPERIMENTAL
Intervention: Sectional matrix system combined with a separation ring (Palodent)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Circumferential matrix system in combination with a retainer (Tofflemire)
Number of subjects: 85
Study: 18495377

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 669

Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 669
Study: 17144123

Group type: EXPERIMENTAL
Intervention: Indomethacin in usual doses (administered in addition to standard therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard therapy (without indomethacin)
Number of subjects: 126
Study: 14512803

Group type: EXPERIMENTAL
Intervention: Poly E ointment applied locally to 27 patients twice a week
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Poly E ointment plus poly E capsule therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Poly E capsule therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: EGCG capsule therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall treatment with green tea extracts
Number of subjects: 51

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 51
Study: 11119735

Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 51
Study: 9179429

Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulphate (180 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 8473554

Group type: EXPERIMENTAL
Intervention: Experimental lipid emulsion formulation of danazol (fasted)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Commercial formulation (hard gelatin capsule) (fasted)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Commercial formulation (hard gelatin capsule) (fed)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Experimental lipid emulsion formulation of danazol (with food)
Number of subjects: 11
Study: 3082023

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate of human plasma (fibronectin)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no fibronectin)
Number of subjects: 31
Study: 29602274

Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF) intervention
Number of subjects: 571

Group type: COMPARATOR
Intervention: Video game attention control
Number of subjects: 571
Study: 27091420

Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 308

Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 308
Study: 24506258

Group type: EXPERIMENTAL
Intervention: X-ray imaging combined with skin stimulation potential-guided percutaneous radiofrequency thermocoagulation of the Gasserian ganglion
Number of subjects: 60

Group type: COMPARATOR
Intervention: C-arm X-ray-guided puncture through the foramen ovale
Number of subjects: 60
Study: 23839118

Group type: EXPERIMENTAL
Intervention: Local lidocaine injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Local saline injection (control)
Number of subjects: 48
Study: 20816593

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 1767
Study: 18058090

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16162696

Group type: COMPARATOR
Intervention: BUD200 (100 microg of budesonide bid plus placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BUD200 + F (100 microg of budesonide bid plus 12 microg of formoterol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BUD (increased to 800 microg bid)
Number of subjects: 40
Study: 12492909

Group type: EXPERIMENTAL
Intervention: Thiocyanate/carbamide peroxide toothpaste (RCP) containing 0.5% SCN-, 0.1% H2O2, and 1450 p.p.m. fluoride
Number of subjects: 140

Group type: COMPARATOR
Intervention: Triclosan toothpaste (Colgate Total) containing 0.3% triclosan, 2.0% PVM/MA, and 1450 p.p.m. fluoride
Number of subjects: 140
Study: 11221809

Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bedtime NPH insulin
Number of subjects: 100
Study: 7856527

Group type: EXPERIMENTAL
Intervention: Stable background therapy
Number of subjects: 209
Study: 2119888

Group type: EXPERIMENTAL
Intervention: Brachial approach to cardiac catheterization
Number of subjects: 202

Group type: COMPARATOR
Intervention: Femoral approach to cardiac catheterization
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Brachial approach
Number of subjects: 202

Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 202
Study: 6988279

Group type: EXPERIMENTAL
Intervention: Traditional low carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified fat diet (high in carbohydrate, low in fat, polyunsaturated to saturated fatty acids ratio of 1.5:1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate diet
Number of subjects: 0
Study: 31648501

Group type: EXPERIMENTAL
Intervention: Apatinib combined with standard first-line chemotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 62
Study: 27052929

Group type: EXPERIMENTAL
Intervention: Wheelchair posture support device (WPSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular care practice
Number of subjects: 16
Study: 26215950

Group type: COMPARATOR
Intervention: Paclitaxel alone (90 mg/m² per week for six cycles of 28 days each; arm A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with bevacizumab (10 mg/kg once every 2 weeks; arm B)
Number of subjects: 52
Study: 24268858

Group type: EXPERIMENTAL
Intervention: Low‐fluence photodynamic therapy (PDT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 32
Study: 22172912

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (RadiaPlex)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Petrolatum gel (Aquaphor)
Number of subjects: 74
Study: 19240602

Group type: EXPERIMENTAL
Intervention: Surgical treatment for unruptured MCA aneurysms
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Surgical treatment for ruptured MCA aneurysms
Number of subjects: 37

Group type: COMPARATOR
Intervention: Surgical treatment for both unruptured and ruptured MCA aneurysms
Number of subjects: 37
Study: 17919379

Group type: EXPERIMENTAL
Intervention: Pleural drainage using central venous catheter (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Simple aspiration by thoracentesis (Group B)
Number of subjects: 46
Study: 10972645

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 12

Group type: COMPARATOR
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 12
Study: 8726155

Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) - 2 puffs or 200 micrograms
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Jet Nebulizer - 5 minutes of nebulization with 100 micrograms/kg
Number of subjects: 23
Study: 1559290

Group type: EXPERIMENTAL
Intervention: Daily wear or extended wear schedule
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-lens wear
Number of subjects: 30

Group type: COMPARATOR
Intervention: Different wear schedules and lens types
Number of subjects: 30
Study: 2414966

Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (HyskonR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 105
Study: 30827574

Group type: EXPERIMENTAL
Intervention: Paper-based cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Order of educational intervention
Number of subjects: 0
Study: 30411125

Group type: EXPERIMENTAL
Intervention: Oral health promotion project (6 months duration)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study: 27512975

Group type: COMPARATOR
Intervention: light‐intensity walking (3.2 km/h for 3 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: simple resistance activities (SRA) for 3 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SIT (uninterrupted sitting)
Number of subjects: 24
Study: 23947915

Group type: EXPERIMENTAL
Intervention: Roxithromycin (ROX)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22713691

Group type: EXPERIMENTAL
Intervention: Pretransplantation ATG-Fresenius (ATG-F)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard graft-versus-host-disease (GVHD) prophylaxis
Number of subjects: 201
Study: 19996984

Group type: EXPERIMENTAL
Intervention: Fospropofol 6.5 mg/kg
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Fospropofol 2 mg/kg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 314
Study: 18713473

Group type: EXPERIMENTAL
Intervention: Reattribution training
Number of subjects: 74
Study: 15976197

Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg . kg(‐1) . min(‐1))
Number of subjects: 140

Group type: COMPARATOR
Intervention: MR(+) group (no intervention)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: M+MR(+) group (milrinone)
Number of subjects: 140
Study: 12629232

Group type: EXPERIMENTAL
Intervention: Patients with mild PD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy seniors
Number of subjects: 16
Study: 10486643

Group type: EXPERIMENTAL
Intervention: Treated hypertensives (G1)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Known but untreated hypertensives (G2)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Newly diagnosed hypertensives (G3)
Number of subjects: 1160
Study: 8903447

Group type: EXPERIMENTAL
Intervention: Nasal cytology indicating allergic pathogenesis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal eosinophils
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis with nasal eosinophilia
Number of subjects: 40
Study: 1721176

Group type: EXPERIMENTAL
Intervention: Atrially-tracked ventricular pacing (Group I)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Rate adaptive AV delay (Group II)
Number of subjects: 13
Study: 31967678

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) added to interval cytoreductive surgery (CRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (CRS) alone
Number of subjects: 0
Study: 29650559

Group type: EXPERIMENTAL
Intervention: COPD care bundle intervention delivered to general practitioners (GPs) and practice assistants
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 216
Study: 27488236

Group type: EXPERIMENTAL
Intervention: 7 vitamin D3-enhanced eggs/week
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 7 25(OH)D3-enhanced eggs/week
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (≤2 eggs/week)
Number of subjects: 55
Study: 25176395

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration followed by PCI
Number of subjects: 7244

Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 7244
Study: 22486135

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 200
Study: 20495139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylephrine 25 μg/min
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg/min
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylephrine 75 μg/min
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylephrine (all doses)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 101
Study: 19114405

Group type: EXPERIMENTAL
Intervention: COF (250 mL of black coffee)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: COF+SUC (black coffee sweetened with 10 g of sucrose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DECAF (decaffeinated coffee)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TEA (black tea)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SUC (10 g sucrose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON (hot water)
Number of subjects: 8
Study: 15953302

Group type: EXPERIMENTAL
Intervention: Therapist-administered relaxation training
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: School-nurse administered relaxation training
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Any form of relaxation training
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Relaxation treatment
Number of subjects: 288

Group type: COMPARATOR
Intervention: Attention-control (ATCO) approaches or self-monitoring (SM) of headaches
Number of subjects: 288
Study: 12578769

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 41

Group type: COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Number of subjects: 41
Study: 10029463

Group type: EXPERIMENTAL
Intervention: Clinical parameters for predicting disc displacement with reduction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clinical parameters for predicting disc displacement without reduction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intermediate zone MRI criterion
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of the most sensitive clinical items
Number of subjects: 160
Study: 8873389

Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Meningococcal polysaccharide vaccine
Number of subjects: 150
Study: 1745841

Group type: EXPERIMENTAL
Intervention: Bromhexine (30 mg capsules three times daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (matched placebo capsules)
Number of subjects: 88
Study: 7050705

Group type: EXPERIMENTAL
Intervention: Activated charcoal (180 g) in divided doses over three days after phenobarbital infusion
Number of subjects: 6
Study: 31959349

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide (CP/ET)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide (CP/ET)
Number of subjects: 394
Study: 31060589

Group type: EXPERIMENTAL
Intervention: Psychologically informed physical therapy (PIPT) training program
Number of subjects: 0
Study: 28554177

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (RIPerC)
Number of subjects: 102
Study: 24691853

Group type: EXPERIMENTAL
Intervention: Topical sucralfate four times a day for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no topical treatment)
Number of subjects: 50
Study: 25158046

Group type: EXPERIMENTAL
Intervention: High-intensity, task-oriented, visual feedback training with a video game balance board (Nintendo Wii) for 12 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (12 weeks without intervention).
Number of subjects: 27
Study: 22024027

Group type: EXPERIMENTAL
Intervention: MitraClip (period 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MitraClip (period 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MitraClip (period 3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MitraClip (all periods)
Number of subjects: 75
Study: 19846848

Group type: EXPERIMENTAL
Intervention: Higher-intensity continuous renal-replacement therapy (40 ml/kg/hour)
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Lower-intensity continuous renal-replacement therapy (25 ml/kg/hour)
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Higher-intensity continuous renal-replacement therapy
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Lower-intensity continuous renal-replacement therapy
Number of subjects: 1508
Study: 17367361

Group type: EXPERIMENTAL
Intervention: Pacemaker diagnostics (Kappa 7‐900, Medtronic, Inc.) detecting atrial high rate episodes (AHRE)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Group II (patients with prior AT history)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Group I (patients without prior AT history)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Both groups after the first month post-implant
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Prior history of AT
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: AHRE diagnostics
Number of subjects: 427
Study: 16379582

Group type: EXPERIMENTAL
Intervention: Anatibant 3.75 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anatibant 22.5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anatibant (both doses)
Number of subjects: 25
Study: 11952185

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study: 9814463

Group type: EXPERIMENTAL
Intervention: Hexarelin (Hex; 2 microg/kg, i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg, i.v.)
Number of subjects: 18
Study: 7657416

Group type: EXPERIMENTAL
Intervention: Semi‐solid carbohydrate feeding
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate feeding
Number of subjects: 31

Group type: COMPARATOR
Intervention: Liquid placebo
Number of subjects: 31
Study: 2504034

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium (Li) added to tricyclic antidepressant
Number of subjects: 30
Study: 975039

Group type: EXPERIMENTAL
Intervention: Weekly combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-drug chemotherapy administered sequentially
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (both weekly and intermittent)
Number of subjects: 0
Study: 30560426

Group type: EXPERIMENTAL
Intervention: Synbiotic capsule (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each, plus 0.8 g/day of inulin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synbiotic capsule
Number of subjects: 60
Study: 28459958

Group type: EXPERIMENTAL
Intervention: TRV027 1 mg/h
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: TRV027 5 mg/h
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: TRV027 25 mg/h
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 26036529

Group type: EXPERIMENTAL
Intervention: Steroid-free regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids for 3 days)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Steroid maintenance regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids maintenance)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Steroid-free regimen
Number of subjects: 428

Group type: COMPARATOR
Intervention: Steroid maintenance regimen
Number of subjects: 428
Study: 23561715

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 120

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study: 22384550

Group type: EXPERIMENTAL
Intervention: Weiyan serial recipes (WYSR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Weifuchun Pill
Number of subjects: 150
Study: 19211408

Group type: EXPERIMENTAL
Intervention: EUSOL (Edinburgh University Solution of Lime)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar
Number of subjects: 0
Study: 16679088

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 260
Study: 15018289

Group type: EXPERIMENTAL
Intervention: Lower-body cooling (LC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Upper-body cooling (UC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No cooling control (CON)
Number of subjects: 8
Study: 11461038

Group type: EXPERIMENTAL
Intervention: Wearing Oxylog mask, heart rate monitor, and Oxylog instrument
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wearing only heart monitor (Control)
Number of subjects: 17
Study: 9726810

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (with antioxidants, amino acids, and nimodipine)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no selenium supplementation)
Number of subjects: 35